ISRCTN47434271 https://doi.org/10.1186/ISRCTN47434271

A randomised trial of paclitaxel combined with platinum-based chemotherapy vs conventional platinum-based chemotherapy in the treatment of women with ovarian cancer

Submission date 06/04/2000	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 06/04/2000	**Overall study status** Completed	
Last Edited 29/10/2021	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Ms Claire Amos

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT00002894

Secondary identifying numbers

ICON4

Study information

Scientific Title
A randomised trial of paclitaxel combined with platinum-based chemotherapy vs conventional platinum-based chemotherapy in the treatment of women with ovarian cancer

Study objectives
To compare paclitaxel combined with platinum to a control arm of conventional platinum-based chemotherapy in the treatment of women with recurrent ovarian cancer.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Ovarian cancer

Interventions
Paclitaxel combined with platinum and the other group receives platinum-based chemotherapy (with no paclitaxel)

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
1. Survival time
2. Quality of life
3. Health economics

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/03/1996

Completion date
31/03/2002

Eligibility

Key inclusion criteria
1. Recurrent epithelial ovarian cancer previously treated with chemotherapy
2. Treatment-free interval of at least 6 months

Participant type(s)
Patient

Age group
Not Specified

Sex
Female

Target number of participants
800 in 5 countries

Total final enrolment
802

Key exclusion criteria
Does not meet inclusion criteria

Date of first enrolment
01/03/1996

Date of final enrolment
31/03/2002

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype

National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	21/06/2003		Yes	No
Plain English results		08/09/2009	29/10/2021	No	Yes